T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
November 06, 2023 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 27, 2023 09:00 ET
|
T-knife Therapeutics
SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting
June 01, 2023 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
February 08, 2023 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
October 20, 2022 08:00 ET
|
T-knife Therapeutics
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors TK-8001 targets a MAGE-A1...
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing...
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
January 05, 2022 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment...
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
November 30, 2021 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that...
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T
November 15, 2021 08:00 ET
|
T-knife Therapeutics
- Preclinical, Translational and Clinical Trial Posters for TK-8001 Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting - Plan to initiate a first-in-human, Phase 1/2...
T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 01, 2021 08:00 ET
|
T-knife Therapeutics
SAN FRANCISCO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three...